Melanoma research highlights rising cases and new pill treatment

In Italy, melanoma diagnoses are increasing, with over 12,900 new cases reported annually and approximately 2,500 deaths. While the five-year survival rate exceeds 90%, specialists from the Intergruppo Melanoma Italiano (IMI) emphasize the need for improved prevention, personalized dermatological checks, and advanced diagnostic tools like artificial intelligence and molecular diagnostics.

In a significant clinical development presented at the European Society for Medical Oncology (ESMO) congress, a new pill called HBI-8000 has shown promise in treating advanced melanoma. When combined with standard immunotherapy (nivolumab), the drug—an HDAC inhibitor—helps ‘strip’ tumor cells of their defenses, making them more visible to the immune system.

Results from the Phase 3 HBI-8000-303 international study indicate that this combination reduces the risk of disease progression by 27% compared to immunotherapy alone. The median progression-free survival increased to 11.7 months, up from 7.4 months in the control group. Additionally, the tumor regression rate rose to 41.4%, compared to 32.3% with standard treatment.